# Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

> **NCT04622462** · — · RECRUITING · sponsor: **Proteocyte Diagnostics Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Oral Neoplasm

## Interventions

- **PROCEDURE:** Standard of Care Histopathology
- **PROCEDURE:** STRATICYTE Assessment

## Key facts

- **NCT ID:** NCT04622462
- **Lead sponsor:** Proteocyte Diagnostics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2015-03-12
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622462, "Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04622462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*